ArticleScientific reports2025
Alteration in epigenetic profile in subclinical atherosclerosis and in high uric acid.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Peripheral Blood HIST1H2AE is a Candidate Epigenetic Biomarker for Coronary Artery Disease: A Multi-Dataset Discovery and Comparative Validation Study.International journal of general medicine · 2026Article
- Epigenetic crosstalk between uric acid and vascular health: a role for extracellular vesicles.Clinical epigenetics · 2025Article
- Common Pathophysiological Mechanisms Connecting Dyslipidemia and Hyperuricemia: a Narrative Review.Maedica · 2025Review
- Molecular and Clinical Perspectives on the Regulation of Sleep and Uric Acid Metabolism.Nature and science of sleep · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uric acid (UA) and epigenetics are associated with cardiovascular diseases (CVD). To identify the association between the epigenetics with UA and subclinical atherosclerosis, three matched groups of males free from cardiovascular risk factors (CVRFs) were compared: candidates for premature coronary angiography (CPCA), individuals with high UA (HUA) and normal subjects (NS). Participants were 30-45 years old: CPCA (n = 18), HUA (n = 15) and NS (n = 20). CVRF freedom was defined as no current smoking/opium, untreated blood pressure < 140/90 mm Hg, fasting glucose < 110 mg/dl, total cholesterol < 240 mg/dl, LDL-) < 160 mg/dl, and HDL-C > 30 mg/dl. HUA was defined as serum UA > 6.5 mg/dl. After adjustment for cofounders (CVRFs), DNMT3A/3B and HDAC3/7 expression profile in peripheral blood mononuclear cells (PBMCs) was analyzed by Real Time PCR technique. In compare to the normal group, the expression of DNMT3B and HDAC3/7 was remarkably lower in CPCA and HUA groups (p-value < 0.05). In the CPCA group, HDAC3 showed the most decrease in the expression. However, they had no considerable correlation with UA levels (ppvalue > 0.05). DNMT3A had a significant increase in the CPCA and HUA groups (p-value < 0.05), and showed a negative correlation with UA levels (p-value ~ 0.044). Alteration in epigenetic factors is independently associated with the presence of early atherosclerosis and with UA levels. Epigenetics is associated with hyperuricemia and with subclinical atherosclerosis, where there is no statistically difference in CVRFs for ischemic heart disease like male sex, old age, diabetes mellitus, hypertension, insulin resistance, hypertriglyceridemia and metabolic syndrome as well as, serum UA levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.